Immunogenic WT-1 peptides and methods of use thereof
View Patent ↗This invention provides mutated WT1 peptides SGQAYMFPNAPYLPSCLES (SEQ ID No:41) and QAYMFPNAPYLPSCL (SEQ ID No:42), immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.
1. An isolated, mutated WT1 peptide, comprising:
a. a binding motif of a human leukocyte antigen (HLA) class II molecule; and
b. a binding motif of an HLA class I molecule, having a point mutation in one or more anchor residues of said binding motif of an HLA class I molecule,
wherein said isolated, mutated WT1 peptide is SGQAYMFPNAPYLPSCLES (SEQ ID No: 41) or QAYMFPNAPYLPSCL (SEQ ID No: 42).
2. The isolated, mutated WT1 peptide of claim 1 , wherein said point mutation increases an affinity of said isolated, mutated WT1 peptide for said HLA class I molecule.
3. The isolated, mutated WT1 peptide of claim 1 , wherein said binding motif of an HLA class I molecule is contained within said binding motif of an HLA class II molecule or overlaps with said binding motif of an HLA class II molecule.
4. An isolated peptide consisting of the amino acid sequence SGQAYMFPNAPYLPSCLES (SEQ ID No: 41) or QAYMFPNAPYLPSCL (SEQ ID No: 42).
5. The isolated, mutated WT1 peptide of claim 1 , wherein said HLA class II molecule is an HLA-DR molecule.
6. The isolated, mutated WT1 peptide of claim 5 , wherein said isolated, mutated WT1 peptide binds to an additional HLA-DR molecule, wherein said HLA-DR molecule and said additional HLA-DR molecule are encoded by separate HLA-DR alleles.
7. The isolated, mutated WT1 peptide of claim 1 , wherein the HLA class II molecule is a HLA-DRB molecule.
8. The isolated, mutated WT1 peptide of claim 7 , wherein said isolated, mutated WT1 peptide binds to an additional HLA-DRB molecule, wherein said HLA-DRB molecule and said additional HLA-DRB molecule are encoded by separate HLA-DR alleles.
9. The isolated, mutated WT1 peptide of claim 1 , wherein said HLA class I molecule is an HLA-A molecule.
10. A composition or vaccine comprising the peptide of claim 1 or 4 , and a physiologically acceptable carrier, adjuvant or combination thereof.
11. The composition or vaccine of claim 10 comprising an additional WT1 peptide other than said peptide.
12. The composition or vaccine of claim 11 , wherein said additional WT1 peptide is selected from the group consisting of: LVRHHNMHQRNMTKL (SEQ ID No: 1), RSDELVRHHNMHQRNMTKL (SEQ ID No: 2), NKRYFKLSHLQMHSR (SEQ ID No: 3), and PGCNKRYFKLSHLQMHSRKHTG (SEQ ID No: 4), or any combination thereof.